Novel Mutations of mtDNA m.14568G>A/m.14568C>T in MT-ND6 and m.7299A>G in MT-CO1: Evidence of Pathogenicity in Leber Hereditary Optic Neuropathy

Leber hereditary optic neuropathy (LHON) is a mitochondrial genetic disease characterized by bilateral, painless, subacute visual failure that develops during young adult life.

Clinical Correspondence Section Editors: Robert Avery, DO Karl C. Golnik, MD Novel Mutations of mtDNA m.14568G.A/m.14568C.T in MT-ND6 and m.7299A.G in MT-CO1: Evidence of Pathogenicity in Leber Hereditary Optic Neuropathy Maria Rizk, MD, Ibrahim Dunya, MD, Georges Azar, MD, Roland Seif, MD, Andre Megarbane, MD, Ama Sadaka, MD L eber hereditary optic neuropathy (LHON) is a mitochondrial genetic disease characterized by bilateral, painless, subacute visual failure that develops during young adult life (1). It is a mitochondrial genetic disease with a maternal pattern of inheritance. Identifying the mutations is important not only in respect to the diagnosis but also as different LHON mutations result in variations of severity and recovery rate in the affected individuals. Ninety-five percent of LHON cases are associated with 1 of 3 primary mutations: m.3460G.A, m.11778 G.A, and m.14484T.C with defect in the mtDNA (mitochondrial DNA) respiratory chain complex I subunit genes MTND1, MT-ND4, and MT-ND6 (mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 1,4, and 6). However, there are many reports about new primary and potential mtDNA mutations associated with LHON from different parts of the world. A genotype–phenotype correlation depending on the mutated gene and the type of pathogenic variant has been discussed in different articles (2). In this report, we discuss the case of 2 young Lebanese patients with LHON who were found to have 2 novel mutations: m.14568G.A/C.T and m.7299A.G (Table 1). CASE PRESENTATION At presentation, a workup was performed looking for infectious, inflammatory, demyelinating, and toxic causes, which was nonrevealing in both patients. Based on history and physical examination, these 2 patients were thought to have LHON, which was confirmed with genetic testing. Genetic testing detected a homoplasmic variant in the MT-ND6 gene m.14568G.A (Patient #1) and Ophthalmology Department (MR, ID, RS, AS), Lebanese American University Medical Center-Rizk Hospital, Beirut, Lebanon; Faculty of Medicine (GA), Eye & Ear University Hospital, Holy Spirit University of Kaslik, Beirut, Lebanon; and Institut Jerome Lejeune (AM), CRB BioJel, Paris, France. The authors report no conflicts of interest. Address correspondence to Ama Sadaka MD, LAU Medical Center— Rizk Hospital, P.O. Box 11-3288, Zahar Street, Beirut, Lebanon; E-mail: [e-mail] 566 m.14568C.T (Patient #2) and a homoplasmic variant in the MT-CO1 gene m.7299A.G in both patients. In addition, the mother of Patient #1 had the same mitochondrial mutation. Patient #1 was compliant with treatment and lifestyle modification. He was started on Idebenone. He was advised to avoid smoking and alcohol. He showed significant improvement on subsequent follow-up, last being 10 months after his initial presentation. Patient #2 unfortunately refused treatment and lifestyle changes and was lost to follow up. DISCUSSION Here, we report on 2 cases with LHON pathogenic variants. The MT-ND6 gene encodes 1 of the 7 mitochondrial subunits of the respiratory Complex I. The 14568 mutation in ND6 gene lies in close vicinity of other LHON-related mutations within the evolutionarily most conserved region of the ND6 gene forming a hydrophobic pocket in the gene, making it a hotspot for LHON (3,4). Mutations involving the specific position 14568 in the mitochondrial ND6 gene are proven to be as causative in LHON (4). It was previously described in the literature in 2 cases only as of pathogenic significance in LHON by Besch et al (3) in 1999. The second mutation found is m.7299A.G in MT-CO1. It involves the cytochrome c oxidase subunit I gene, which is 1 of the 3 mitochondrial DNA encoded subunits of respiratory Complex IV. Mutations involving the MT-CO1 gene are proven to be involved in LHON, and this genotype– phenotype correlation is previously described in the literature (5). However, the specific variant found in our 2 patients involving the position 7,299 has not been previously described and there are no data in the literature concerning this mutation and its pathogenicity in LHON (5). It is important to note that secondary mutations are previously described in LHON, specifically in the ND6 gene. Altogether, 7 mutations in ND6 gene are described in the same hydrophobic transmembrane helix of the ND6 gene: 14459, 14482, 14484, 14495, 14498, 14568, and 14596, making it a mutational hotspot for the disease (4). Rizk et al: J Neuro-Ophthalmol 2020; 40: 566-568 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. Clinical Correspondence TABLE 1. Ophthalmologic examination of Patient #1 and Patient #2 at presentation and on follow-up Patient #1, 24-Year-Old At Presentation (1 Month After Onset of Symptoms) Visual acuity OD OS Pupils Intraocular pressure (IOP) OD OS Color vision OD OS Fundus examination Visual field Extraocular movements/slit lamp examination Counting fingers at 2 feet - pinhole 20/100 20/40 - pinhole 20/30 Equal, reactive, no relative afferent pupillary defect (RAPD) 10 Months Later 20/30 20/40 Equal, reactive, no RAPD 13 14 15 17 4/14 11/14 Full and hyperemic discs Central and centrocecal scotomas in OD . OS Normal 8/14 9/14 Less full and hyperemic discs Improved Normal Patient #2, 16-Year-Old Visual acuity OD OS Pupils IOP OD OS Color vision OD OS Fundus examination Visual field Extraocular movements/slit lamp examination At Presentation (8 Months After Onset of Symptoms) 3 Months Later Counting fingers 20/400 Equal, reactive, no RAPD 20/400 20/150 Equal, reactive, no RAPD 14 15 14 15 4/14 5/14 Pale optic nerve head with normal macula and vessels OU Cecocentral scotomas OU Normal This adds further evidence that the 14568 mutation is of pathogenic significance and that this region may be useful to sequence in patients where no known LHON mutations are found. Also, secondary mutations were previously suggested and suspected to increase the penetrance of a primary LHON mutation (4). This is another strong argument in favor of the significance of the 2 secondary mutations found in this report. Whether the phenotype of LHON in these patients is due to the synergistic presence of the 2 mutations involving both MT-CO1 and MT-ND6 genes or only due to the presence of the mutation involving the MTND6 gene is yet to be determined. Even if the Rizk et al: J Neuro-Ophthalmol 2020; 40: 566-568 5/14 6/14 Pale optic nerve head with normal macula and vessels OU Cecocentral scotomas OU Normal m.7299A.G in MT-CO-1 is not the primary cause of LHON in this patient, it still could be an exacerbating risk factor. To note that vision of Patient #1 improved with time. The main difference between the 2 patients was the time of presentation after initial vision loss and lifestyle changes including treatment with Idebenone, which Patient #1 followed and was the one with significantly better outcomes. We realize that this could be due to chance alone; however, this observation raises the possibility of different mutations having different phenotypic outcomes in LHON and stresses the importance of avoiding mitochondrial stressors such as smoking and the possible benefit of starting 567 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited. Clinical Correspondence treatment with Idebenone as early as possible, as proven in several studies such as the Rescue of Hereditary Optic Disease Outpatient Study (6). In addition to that, we raise the possibility of different mutations existing in different parts of the world and affecting the phenotypic outcome of the patients’ disease. Both of our patients are Lebanese and of Lebanese descent. Therefore, a better knowledge of the mtDNA mutations related to LHON and their interaction is crucial and will further improve the sensitivity and reliability of mtDNA based diagnostics (2). Also, establishing geographic distribution of the mutations might help diagnose and understand the prognosis of LHON patients and will lead to better counseling of these patients. However, these findings have some limitations. In fact, although these results can help confirm the diversity of LHON clinical phenotypes and increase the understanding of the clinical features of LHON patients with rare mtDNA mutations, it does not provide data to further explain potential mechanisms of the mutations. In addition, there are no previous data concerning our patients’ population, which makes it harder to prove the pathogenicity of the 2 uncommon secondary mutations found. CONCLUSION We suggest that more advanced genetic testing of patients must be performed to establish more accurate references for 568 mtDNA based diagnosis and prognosis of LHON. We also suggest that different populations might have different genetic and phenotypic presentation of LHON. Further studies can help establish geographic distribution of the mutations as well as aid in understanding the prognosis and treatment for those patients. REFERENCES 1. Yu-Wai-Man P, Turnbull DM, Chinnery PF. Leber hereditary optic neuropathy. J Med Genet. 2002;39:162–169. 2. Wissinger B, Besch D, Baumann B, Fauser S, Christ-Adler M, Jurklies B, Zrenner E, Leo-Kottler B. Mutation analysis of the ND6 gene in patients with Lebers hereditary optic neuropathy. Biochem Biophys Res Commun. 1997;234:511–515. 3. Besch D, Leo-Kottler B, Zrenner E, Wissinger B. Leber’s hereditary optic neuropathy: clinical and molecular genetic findings in a patient with a new mutation in the ND6 gene. Graefes Arch Clin Exp Ophthalmol. 1999;237:745–752. 4. Fauser S, Leo-Kottler B, Besch D, Luberichs J. Confirmation of the 14568 mutation in the mitochondrial ND6 gene as causative in Leber’s hereditary optic neuropathy. Ophthalmic Genet. 2002;23:191–197. 5. Brown MD, Yang CC, Trounce I, Torroni A, Lott MT, Wallace DC. A mitochondrial DNA variant, identified in Leber hereditary optic neuropathy patients, which extends the amino acid sequence of cytochrome c oxidase subunit I. Am J Hum Genet. 1992;51:378–385. 6. Carelli V, Carbonelli M, de Coo IF, Kawasaki A, Klopstock T, Lagrèze WA, Lagrèze WA, La Morgia C, Newman NJ, Orssaud C, Pott JWR, Sadun AA, van Everdingen J, Vignal-Clermont C, Votruba M, Yu-Wai-Man P, Barboni P. International consensus statement on the clinical and therapeutic management of leber hereditary optic neuropathy. J Neuroophthalmol 2017;37:371– 381. Rizk et al: J Neuro-Ophthalmol 2020; 40: 566-568 Copyright © North American Neuro-Ophthalmology Society. Unauthorized reproduction of this article is prohibited.